leisure time -WSS

leisure time

author：hotspot 2025-10-08 21:09:38 - browse：81

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Key Senate panel to consider PBM, drug pricing reform package

explore

Wikipedia

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Brain injuries and the importance of a second opinion

Xenotransplantation trials will require adjusting expectations, experts say

Biden administration plans revamp of organ transplant system

Prime Medicine says its gene editing passes test in monkeys

explore

leisure time

explore

Drug repurposing or repositioning? The language matters

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Medicare proposal to cover medical devices draws a mixed reaction

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Novavax promises a turnaround & Lilly roils the obesity market

Inside the rise of 'mukbang' eating videos

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After Sarepta trial failure, Duchenne families brace for more debate

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Life sciences investors close nearly $6 billion in new funds

hotspot

How to convince healthy people to buy insurance

How to convince healthy people to buy insurance

Coloradans with cystic fibrosis could lose access to Trikafta

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Novo pauses ads for weight loss drug Wegovy amid demand

Timeline: Key moments in fight for gay rights

focus

explore

Wikipedia

knowledge